Company
Destiny Pharma PLC
LON:DEST
Destiny Pharma PLC is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.
97 stories · page 2 of 5
Destiny Pharma partners with Sebela to take C.diffcile treatment through phase 3
C. difficile is one of the leading causes of hospital-acquired infection in the US
Destiny Pharma kicks off safety study of dermal formulation of key asset
The company has reformulated its nasal gel to treat post-operative infections into a skin application
Destiny Pharma gets reiterated 306p target price from finnCap following positive R&D update
The analysts noted that the entire meeting was focused on Destiny's late-stage assets, NTCD-M3 and XF-73, its development plans, competitive positioning, and market potential
Destiny Pharma's interims reveal the company has made good operational progress, says broker
finnCap tweaked its forecasts in the wake of the numbers
Archive
Small Cap Feast - accesso Technology, Destiny Pharma, Thor Mining, and more...
07 September 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:Stanley Gibbons Group has left AIM. What’s cooking in the IPO kitchen?
Destiny Pharma hails positive feedback from European regulator for C. difficile phase III trial
The European Medicines Agency has said a single, final-stage study will be enough to make a marketing authorisation application
Destiny Pharma close to delivering partnership for phase III asset
The company provided an update in an overview briefing of its progress to date
Destiny Pharma hails study that underlines safety of lead asset
The biotech is making final preparations to take NTCD-M3, a new antibiotic treatment for CDI, into phase III clinical trials
Destiny Pharma to trial nasal antibiotic in breast surgery after 'positive' FDA feedback
"If this compound is successful, it would be a game changer and revolutionise the safety of breast reconstruction surgery" Alexander F Mericli, Associate Professor of Plastic Surgery at The University of Texas MD Anderson Cancer Center, sai